Mangoceuticals, Capex To Revenue from 2010 to 2025

MGRX Stock   2.61  0.07  2.61%   
Mangoceuticals, Common Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue will likely drop to 0.01 in 2025. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.005532
Current Value
0.005256
Quarterly Volatility
1.94163055
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mangoceuticals, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangoceuticals, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.4 K, Interest Expense of 0.0 or Selling General Administrative of 7.8 M, as well as many indicators such as Price To Sales Ratio of 8.85, Dividend Yield of 0.0 or PTB Ratio of 7.23. Mangoceuticals, financial statements analysis is a perfect complement when working with Mangoceuticals, Common Valuation or Volatility modules.
  
Check out the analysis of Mangoceuticals, Common Correlation against competitors.

Latest Mangoceuticals, Common's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Mangoceuticals, Common Stock over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Mangoceuticals, Common's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mangoceuticals, Common's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Mangoceuticals, Capex To Revenue Regression Statistics

Arithmetic Mean3.92
Geometric Mean1.34
Coefficient Of Variation49.55
Mean Deviation1.47
Median4.82
Standard Deviation1.94
Sample Variance3.77
Range4.817
R-Value(0.68)
Mean Square Error2.19
R-Squared0.46
Significance0
Slope(0.28)
Total Sum of Squares56.55

Mangoceuticals, Capex To Revenue History

2025 0.005256
2024 0.005532
2023 0.004811

About Mangoceuticals, Common Financial Statements

Mangoceuticals, Common investors use historical fundamental indicators, such as Mangoceuticals, Common's Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mangoceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.